Second-line therapy for patients with diabetes inadequately controlled on metformin: a systematic review and cost-effectiveness analysis
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001581
English
Authors' objectives:
1) To conduct a systematic review of the clinical evidence pertaining to second-line antidiabetes drugs for patients with type 2 diabetes inadequately controlled on metformin monotherapy.
2) To conduct a cost-effectiveness analysis of second-line antidiabetes drugs for patients with type 2 diabetes inadequately controlled on metformin monotherapy based on the results of the systematic review.
Authors' recommendations:
Sulfonylureas are equally efficacious as other agents when used as second-line treatment after inadequate control with metformin monotherapy, and represent the most cost-effective treatment option.
Details
Project Status:
Completed
URL for project:
http://cadth.ca/media/pdf/C1110_SR_Report_final_e.pdf
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Cost-Benefit Analysis
- Hypoglycemic Agents
- Metformin
- Sulfonylurea Compounds
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.